Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 20, 2014, Pages 8871-8876

  Misirlioglu, Hasan Cem ^a   Coskun Breuneval, Mehtap ^a,b   Kucukpilakci, Bulent ^a   Ugur, Vahide Isil ^a   Elgin, Yesim ^a   Demirkasimoglu, Taciser ^a   Kara, Sakire Pinar ^a   Ozgen, Aytul ^a   Sanri, Ergun ^a   Guney, Yildiz ^a  

^a ANKARA ONCOLOGY HOSPITAL   (Turkey)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Adjuvant radiotherapy; Chemoradiotherapy; Gastric cancer; Prognosis; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; CANCER STAGING; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SIGNET RING CELL; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH NEOPLASMS; SURVIVAL RATE; TIME; TUMOR INVASION; YOUNG ADULT;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SIGNET RING CELL; CHEMORADIOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84911127206     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.20.8871     Document Type: Article

References (26)

1. Agboola O (1994). Adjuvant treatment in gastric cancer. Cancer Treat Rev, 20, 217-240
2. Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20
3. Czito BG, Palta M, Willett CG (2013). Stomach cancer. In: "Perez and Bradys Principles and Practice of Radiation Oncology 6th edition", Eds Halperin EJ, Wazer DE, Perez CA, Brady LW. Lippincott Williams &Wilkins, Philadelphia pp. 1165-88
4. de Aretxabala X, Konishi K, Yonemura Y, et al (1987). Node dissection in gastric cancer. Br J Surg, 74, 770-773
5. Dockerty M (1964). In "Cancer of the Stomach, Pathologic Aspects of Primary Malignant Neoplasms of the Stomach", eds ReMine W, Priestley J, Berkson J, WB Saunders, Philadelphia, PA, p 173
6. Douglass HO Jr, Nava HR (1985). Gastric adenocarcinoma-management of the primary disease. Semin Oncol, 12, 32-45
7. Gao LL, Feng L, Yao ST, et al (2011). Molecular mechanisms of celery seed extract induced apoptosis via s phase cell cycle arrest in the BGC-823 human stomach cancer cell line. Asian Pac J Cancer Prev, 12, 2601-6
8. Hajmanoochehri F, Mohammadi N, Nasirian N, Hosseinkhani M (2013). Patho-epidemiological features of esophageal and gastric cancers in an endemic region: a 20-year retrospective study. Asian Pac J Cancer Prev, 14, 3491-7
9. Hartgrink HH, van de Velde CJ, Putter H, et al (2004). Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol, 22, 2069-77
10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90
11. Jing YM, Guo SX, Zhang XP, et al (2012). Association between C1019T polymorphism in the connexin 37 gene and Helicobacter pylori infection in patients with gastric cancer. Asian Pac J Cancer Prev, 13, 2363-7
12. Kim S, Lim DH, Lee J, et al (2005). An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys, 63, 1279-85
13. Lee J, Lim Do H, Kim S, et al (2012). Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol, 30, 268-73
14. Macdonald JS, Smalley SR, Benedetti J, et al (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345, 725-30
15. Martoni A, Cricca A, Guaraldi M, et al (1989). A randomized clinical trial with a weekly regimen of 5-fluorouracil with or without folinic acid in advanced gastrointestinal adenocarcinomas: a preliminary report. J Chemother, 1, 197-202
16. Ohri N, Garg MK, Aparo S, et al (2013). Who Benefits From Adjuvant Radiation Therapy for Gastric Cancer? A Meta- Analysis. Int J Radiat Oncol Biol Phys, 86, 330-5
17. Serlin O, Keehn RJ, Higgins GA Jr, et al (1977). Factors related to survival following resection for gastric carcinoma: analysis of 903 cases. Cancer, 40, 1318-29
18. Smalley SR, Benedetti JK, Haller DG, et al (2012). Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection. J Clin Oncol, 30, 2327-33
19. Songun I, Putter H, Kranenbarg EM, et al (2010). Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 11, 439-49
20. Takeda S, Taguchi T, Ohta J, et al (1995). A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group). Gan To Kagaku Ryoho, 22, 903-10
21. Tamura S, Takeno A, Miki H (2011). Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol, 2011, 748-5
22. Van Cutsem E, Van de Velde C, Roth A, et al (2008). Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC).-gastrointestinal cancer group. Eur J Cancer, 44, 182-194
23. Vanhoefer U, Wilke H, Weh HJ, et al (1994). Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol, 5, 850-1
24. Wani M, Afroze D, Makhdoomi M, et al (2012). Promoter methylation status of DNA repair gene (hMLH1). in gastric carcinoma patients of the Kashmir valley. Asian Pac J Cancer Prev, 13, 4177-81
25. Zhang WY, Zhang WJ, Bai Y, et al (2013). Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis. Asian Pac J Cancer Prev. 14, 381-6
26. Zhu WG, Xua DF, Pu J, et al (2012). A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol, 104, 361-6